CG Oncology (CGON) on Monday reported durable long-term outcomes from its phase 3 Bond-003 trial evaluating cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer, or NMIBC, unresponsive to Bacillus Calmette Guerin.
In Cohort C, 75.5% of patients achieved a complete response at any point during the study. At 24 months, 42.3% remained in complete response by Kaplan-Meier estimate, with 97.3% free from progression to muscle-invasive disease and 91.6% of initial responders remaining cystectomy-free.
Early results from Cohort P, in patients with BCG-unresponsive Ta/T1 disease without carcinoma in situ, showed a 90.5% high-grade recurrence-free survival rate at both three and nine months. Treatment was well-tolerated with no grade 3 or higher treatment-related adverse events reported.
The company is continuing to evaluate the therapy for potential regulatory submission.
Shares of CG Oncology rose 34% in recent trading activity.
Price: 30.06, Change: +7.69, Percent Change: +34.38
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.